Move over, Zolgensma. A new one-dose therapy that could provide a similar mode of treatment for the red-hot therapy area of neurodegenerative disorders has received orphan designation from regulators on both sides of the Atlantic.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,